ARTICLE SUMMARY:
A new report from UCLA Biodesign and the Boston Consulting Group confirms that the US has replaced Europe as the first market of choice for medtech innovation due to improvements at FDA and MDR-based confusion in the EU; reimbursement remains the leading obstacle for all innovative products. Also in this issue: we speak with Jeff Shuren about the MDUFA V deal, dive into ongoing user-fee negotiations on the Hill, and take a look at CMS' 2023 physician pay proposal.
